argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP
argenex (ARGX) had its price target lowered by Oppenheimer Holdings, Inc. from $1,060.00 to $1,014.00. They now have an "outperform" rating on the stock.
argenx announces Annual General Meeting of Shareholders on May 6, 2026
Analysts Highlight Vyvgart Expansion as Major Growth Driver for Argenx (ARGX) [Yahoo! Finance]
argenex (ARGX) was upgraded by Deutsche Bank Aktiengesellschaft from "hold" to "buy".